RESUMO

BACKGROUND: In recent years, a new type of immediate hypersensitivity reaction known as cytokine release began to emerge, and within this phenotype of reactions, interleukin-6 is the most frequently associated with the presence during drug administration. Chemotherapeutic agents (QT) and monoclonal antibodies. OBJECTIVE: Determine interleukin-6 levels in hypersensitivity reactions to QT and monoclonal antibodies. METHODS: Observational and prospective study that was carried out from March 1, 2021 to March 1, 2022 in a university hospital in northeastern Mexico. Symptoms, severity, interleukin-6 levels, and skin tests of hypersensitivity reaction were evaluated at QT and monoclonal antibodies. RESULTS: A total of 41 patients with oncological disease were included, the most frequent being ovarian cancer. Symptoms as initial hypersensitivity reaction were neuromuscular in taxanes and cutaneous in Platinums.41.5% presented elevation of interleukin-6, and it was found more frequently in presence of metastases. Positive skin tests were found more frequently in the carboplatin and doxorubicin groups. The most frequently presented phenotype was type I in paclitaxel, carboplatin, and doxorubicin, and mixed-reaction (type I and cytokine release) in oxaliplatin. CONCLUSION: With the increasing prevalence of hypersensitivity reactions to biologic and antineoplastic therapies, interleukin-6 should be recognized as a biomarker in immediate hypersensitivity reactions to QT and monoclonal antibodies.

RESUMO

BACKGROUND: Any substance used as a treatment for any disease can produce harmful or unpleasant events called adverse drug reactions (ADRs). They are due to inherent biological effects of the drug and are caused by immunological and non-immunological mechanisms. OBJECTIVES: To describe the immunological mechanisms of hypersensitivity reactions (HSR) to drugs, their epidemiology, risk factors, classification, clinical manifestations, diagnosis, treatment, and prognosis. METHODS: A review of the most current literature in English and Spanish was carried out, in the main databases, related to the HSR of various drug groups. RESULTS: This study describes the terms used to define ADRs and HSRs, their classification and clinical manifestations, current diagnostic tools, treatment algorithms and prognosis of the most frequently used medications and with the highest prevalence of reported adverse events. CONCLUSION: ADRs are a challenging entity, with a complex pathophysiology that has not been fully understood. Its approach requires a careful consideration since not all drugs have validated tests for their diagnosis nor a specific treatment. When indicating the use of any drug, the severity of the disease, the availability of other treatments and the potential risks of developing future adverse events should always be taken into consideration.

ANTECEDENTES: Cualquier sustancia prescrita en el tratamiento de algún padecimiento es capaz de producir eventos dañinos o desagradables, y se denominan reacciones adversas a medicamentos. Estas reacciones se originan por mecanismos inmunológicos y no inmunológicos. OBJECTIVOS: Describir los mecanismos inmunológicos de las reacciones de hipersensibilidad a medicamentos, epidemiologia, factores de riesgo, clasificación, manifestaciones clínicas, diagnóstico, tratamiento y pronóstico. MÉTODOS: Se revisó la bibliografía actualizada, en inglés y español, asociada con reacciones de hipersensibilidad a medicamentos en las principales bases de datos. RESULTADOS: Se describen los términos para definir las reacciones adversas y de hipersensibilidad a medicamentos, su clasificación y manifestaciones clínicas, métodos diagnósticos actuales y en estudio, algoritmos de tratamiento y pronóstico de los medicamentos más frecuentemente prescritos y con mayor prevalencia de eventos adversos reportados. CONCLUSIÓN: Las reacciones adversas a medicamentos representan un reto, con una fisiopatología compleja y no del todo comprendida. Su abordaje requiere un enfoque cuidadoso, porque no todos los fármacos cuentan con pruebas validadas para establecer el diagnóstico y tratamiento específico. Antes de indicar cualquier medicamento debe considerarse la gravedad de la enfermedad, disponibilidad de otros tratamientos y riesgos potenciales de sufrir eventos adversos.

Assuntos

RESUMO

BACKGROUND: Taxanes adjuvant therapy is recommended in certain high risk or metastatic tumors, particularly in lung and breast cancer, but also in other types of cancer like ovarian. The incidence of severe adverse drug reactions to paclitaxel is of approximately 10%. OBJECTIVES: Analyze type I hypersensitivity reactions to paclitaxel and their management in the Mexican population. METHOD: It is a retrospective, observational and descriptive study that included type I hypersensitivity reactions to paclitaxel reported from our database. Symptoms of hypersensitivity reactions to paclitaxel were classified and skin testing was performed with a 6 mg/mL paclitaxel concentration. The desensitization procedure consisted of a 12-steps, 3-bags of 250 mL protocol with a 6-7-hour duration. RESULTS: A total of 60 desensitization procedures were performed and were all completed successfully. All participants in our group were female, their median age was 44.5 years.All of our patients had hypersensitivity adverse drug reaction to paclitaxel during their first exposure and within the first 10 minutes of infusion. 63.6% of the patients had a moderate hypersensitivity reaction to paclitaxel and 36.4% had a severe reaction. CONCLUSIONS: Paclitaxel continues to be a common use drug and has a high rate of adverse drug reactions. This is the first study of hypersensitivity to paclitaxel in a Mexican population.

Assuntos

RESUMO

BACKGROUND: Gestational syphilis is underdiagnosed and undertreated, leading to stillbirth, prematurity, low birthweight, neonatal death, and congenital syphilis. Most patients who label as allergic to penicillin are misdiagnosed. OBJECTIVE: To assess the efficacy and safety of an algorithm to guide re-exposure to penicillin in pregnant women with syphilis and reporting allergy to the antibiotic. METHODS: We performed a prospective study assessing pregnant women with syphilis and labeled as allergic to penicillin. Based on clinical history, patients were divided in two groups: high-risk and low-risk to penicillin allergy. Low-risk patients with negative skin testing and negative serum specific IgE to penicillin underwent drug provocation test. The remaining patients underwent desensitization. RESULTS: Ninety-one patients were enrolled. Allergy to penicillin was confirmed in 7.69% of pregnant women with syphilis and clinical history of allergy to penicillin; in all cases the diagnosis was made through intradermal testing, which predicted 100% of the breakthrough reactions observed during rapid drug desensitization (p < 0.001). Risk stratification based on the initial clinical reaction and skin testing to guide penicillin re-introduction through drug challenge or desensitization was safe (97.8%) and effective (97.8%). CONCLUSION: We developed and showed the efficacy and safety of an algorithm to guide re-exposure to penicillin in pregnant women with syphilis and labeled as allergic to this drug. Intradermal test is an excellent biomarker in the diagnosis of immediate hypersensitivity reaction to penicillin and to predict breakthrough reaction during rapid drug desensitization. Further studies may confirm the greater safety of the intravenous protocol compared to the oral protocol.

RESUMO

Hypersensitivity reactions can be complex and life-threatening to patients, especially when drugs such as ß-lactam antibiotics are involved. To this day, there are diagnostic algorithms and mobile applications that improve the clinical approach, as well as laboratory tests and more specialized procedures, such as skin tests and controlled exposure tests; which are useful for identifying the drug involved and for selecting safe and effective therapeutic alternatives. For several years, the desensitization procedure has been positioned as a vital tool for clinical allergists and for their patients, and it is key to improving clinical outcomes such as survival and quality of life.

Las reacciones de hipersensibilidad pueden ser complejas y poner en peligro la vida de los pacientes, más cuando se involucran medicamentos como los antibióticos betalactámicos. A la fecha, se dispone de algoritmos diagnósticos y aplicaciones móviles que facilitan el abordaje clínico, así como pruebas de laboratorio y procedimientos más especializados, como las pruebas cutáneas y de exposición controlada, útiles para la identificación de la sustancia implicada y para la selección de alternativas terapéuticas seguras y efectivas. Desde hace varios años, el procedimiento de desensibilización se ha posicionado como una herramienta vital para el alergólogo clínico y los pacientes, y es clave para mejorar los desenlaces clínicos, tanto la supervivencia como la calidad de vida.

Assuntos

RESUMO

OBJECTIVE: Female sex, body mass index (BMI), and neuromuscular blocking agents are risk factors of perioperative hypersensitivity reactions. This study aimed to investigate the effect of rocuronium on serum tryptase concentrations during general anesthesia in overweight and obese women. METHODS: The study was conducted in two groups: Group I (n=66) underwent volatile anesthesia with rocuronium and group II (n=60) underwent volatile anesthesia without any muscle relaxant. Serum tryptase concentration (STC) measurements were performed at baseline (STC 0) and postoperatively (STC 1). ClinicalTrials.gov: NCT04035707 RESULTS: The highest median value of STC 0 was seen in obese patients (3.44 μg L-1) and it was significantly higher than in overweight (p=0.01) and underweight patients (p=0.03). The maximum STC 0 was observed in overweight patients (20.4 μg L-1). In group I, STC 0 in obese patients presented the highest median value (4.49 μg L-1), and was significantly higher than in overweight patients (p=0.03), and had significantly higher STC 1 than patients with normal BMI (p=0.04). STC 0 and STC 1 in overweight and obese female patients did not differ significantly between groups. STC 1 did not correlate with rocuronium doses. In group I, BMI positively correlated with the duration of rocuronium infusion (rho=0.37) and STC 1 positively correlated with BMI (rho=0.32). CONCLUSION: Excess weight and obesity predispose to higher preoperative serum tryptase values. Postoperative STC is not linked to rocuronium doses. BMI is the main determinant factor of STC during combined volatile general anesthesia.

Assuntos

RESUMO

Food additives are ingredients that are intentionally added to food in order to modify its physical, chemical, biological, or sensorial characteristics. Food additives may act as allergens and generate IgE-mediated immune reactions, or they may act as pseudo allergens and generate non-IgE-mediated immune reactions. Such reactions can generate diverse clinical pictures or they may exacerbate diseases as diverse as eosinophilic esophagitis, bronchial asthma, atopic dermatitis, contact dermatitis, chronic urticaria, or anaphylaxis. Thousands of food additives are being used daily in industrialized countries and, although their use has been globalized, there is not much science information about their adverse effects; especially about their hypersensitivity reactions that, despite being reported in literature as rare, it is probably because they are under-diagnosed due to the fact that they require a high level of clinical suspicion by the physician, and the proof of a causal connection between the symptomatology and the food additive. Hypersensitivity reactions to food additives must be suspected in patients who report symptoms with the intake of multiple commercially prepared foods or to a commercially prepared food without presenting symptoms with the intake of the natural or homemade version of the same food or with the presence of idiopathic reactions. The diagnostic role of the in vivo or in vitro test against IgE (Skin Tests or RAST) is limited to some natural food additives. The gold standard diagnosis that shows causality between the additive and the symptoms is the oral food challenge. The treatment shall always be the elimination of the food additive from the patient's diet.

Los aditivos alimentarios son ingredientes agregados intencionalmente para modificar las características físicas, químicas, biológicas o sensoriales de los alimentos; pueden actuar como alérgenos y generar reacciones inmunológicas mediadas por IgE o como pseudoalérgenos y generar reacciones inmunológicas no mediadas por IgE. Dichas reacciones pueden provocar diversos cuadros clínicos o exacerbar diferentes enfermedades: esofagitis eosinofílica, asma bronquial, dermatitis atópica, dermatitis de contacto, urticaria crónica o anafilaxia. Diariamente, miles de aditivos alimentarios son utilizados en países industrializados y aunque su uso se ha globalizado, se dispone de poca información científica sobre sus efectos adversos, particularmente sobre las reacciones de hipersensibilidad, las cuales son raras en la literatura, muy probablemente porque son infradiagnosticadas debido a que requieren un alto grado de sospecha clínica por parte del médico y la demostración de una relación de causalidad entre la sintomatología y el aditivo alimentario. Las reacciones de hipersensibilidad a aditivos alimentarios deben ser sospechadas en paciente con reporten síntomas a múltiples alimentos o a un alimento de preparación comercial sin sintomatología ante la ingesta natural o casera del mismo o ante reacciones idiopáticas. El papel diagnóstico de la prueba in vivo o in vitro contra IgE (pruebas cutáneas o RAST) está limitado a algunos aditivos alimentarios naturales. La prueba diagnóstica que demuestra causalidad entre el aditivo y la sintomatología es el reto oral alimentario. El tratamiento deberá ser siempre la eliminación del aditivo de la dieta.

Assuntos

RESUMO

PURPOSE OF REVIEW: The aim of this study is to critically review the relevant literature published on basophil activation test, presenting the current knowledge and future perspectives. RECENT FINDINGS: Basophil activation test (BAT) results varied accordingly to the class of the drug studied, and have promising results in immediate hypersensitivity reactions to pyrazolone (selective reactors), neuromuscular blockers, beta-lactams, and platinum compounds, all examples of classical IgE-mediated hypersensitivity drug reactions. Currently, BAT is applied in research settings, but based in the results of our review, the test can be considered as a diagnostic tool for daily practice for selected patients and selected drugs, when the test is available, particularly for patients who experienced severe reactions and when diagnosis cannot be stablished by serum-specific IgE and skin testing, in order to avoid unnecessary drug provocations tests.

Assuntos

RESUMO

OBJECTIVES: Patients with breast cancer who receive weekly paclitaxel therapy may experience deleterious effects associated with prophylactic dexamethasone use for 12 consecutive weeks. Approximately 90% of paclitaxel hypersensitivity reactions (HSRs) occur within the first 10 to 15 min of the first two infusions. We investigated the feasibility of dexamethasone withdrawal between weeks 3 and 12 (W3 and W12) in early stage breast cancer patients treated with weekly paclitaxel at the standard dose (80 mg/m2). METHODS: All patients received intravenous prophylaxis of dexamethasone 20 mg, ranitidine 50 mg, and diphenhydramine 50 mg in the first 2 weeks (W1 and W2) of treatment. Provided that no serious (G3/G4) HSRs events occurred, dexamethasone was omitted between W3 and W12, while ranitidine and diphenhydramine were continued. The primary end point was the incidence of any grade HSRs during the treatment period, and the secondary end points were quality of life and weight changes. RESULTS: Twenty-five patients were included in the study, and 300 infusion cycles of paclitaxel were evaluated for HSRs. The overall incidence of HSRs was 0.6% (2 events), and both of these events occurred in the first week. There were no incidents of serious HSRs or anaphylaxis and no G3 or G4 toxicities. Scores from the EORTC QLQ-C30 questionnaire did not change significantly for the global health status/quality of life scale or for the symptoms scales, although changes in scores differed significantly for the functional scales. There were no clinically relevant weight changes during the treatment period. CONCLUSIONS: Dexamethasone withdrawal from W3 to W12 in early stage breast cancer patients treated with weekly paclitaxel is feasible. The incidence of all grades of HSRs was comparable to that reported in trials with dexamethasone for 12 consecutive weeks, and no serious events (G3/G4) occurred. Studies with larger sample sizes are needed to confirm our results which are important, especially for patients for whom corticosteroids are contraindicated.

Assuntos

RESUMO

A identificação e descrição das propriedades do receptor MrgprX2 possibilitou maior compreensão das funções dos mastócitos nas reações de hipersensibilidade não alérgicas, assim como em processos inflamatórios e infecciosos. Neste artigo revisamos brevemente as principais funções deste receptor, enfatizando seu papel nas reações de hipersensibilidade a medicamentos, promovendo a desgranulação direta de mastócitos.

The Identification identification of the receptor MRGPRX2 receptor and the description of its properties has improved the knowledge about mast cell actions in non-allergic hypersensitivity reactions, as well as in inflammatory and infectious processes. In this paper we briefly review the main functions of this receptor, highlighting its role in the drug-induced hypersensitivity reactions, with direct degranulation of mast cells.

Assuntos

RESUMO

Os casos de reações de hipersensibilidade à dieta parenteral são muito raros. Determinar o agente etiológico nestes casos não é uma tarefa fácil, pois são muitos os componentes que podem causar a reação, e também por não haver padronização adequada dos testes. Outro problema enfrentado é a dificuldade ao acesso aos elementos da dieta para os testes. Descrevemos um caso clínico e toda a investigação diagnóstica detalhada de anafilaxia por dieta parenteral em um paciente adulto, tendo como principal agente suspeito o polietilenoglicol (PEG). Os polietilenoglicóis, ou macrogóis, compreendem uma família de polímeros hidrofílicos amplamente utilizados em produtos industrializados farmacêuticos, alimentares e cosméticos. Nenhum estudo até agora examinou a prevalência da hipersensibilidade ao PEG, e a ocorrência é provavelmente subestimada. A suspeita de alergia ao PEG deve ser considerada em: pacientes com reações de hipersensibilidade do tipo imediata (RHI) para produtos contendo PEG, nos quais a sensibilização aos ingredientes ativos foi excluída; pacientes com RHI repetidas com medicamentos e produtos não relacionados; e em pacientes com RHI para apenas certas marcas ou doses do mesmo medicamento. RHI aos medicamentos PEGuilados estão bem estabelecidas, porém IgE específica contra o PEG ainda não foi identificada. Este relato mostra que os produtos normalmente considerados como inócuos não devem estar acima de suspeitas durante a investigação alergológica.

Case reporting of hypersensitivity reactions to parenteral diet is rare. Determining the etiologic agent in those cases is not an easy task because many components may cause a reaction and tests are not adequately standardized. Another problem is difficulty in accessing items of the diet for the tests. We describe a clinical case with a detailed diagnostic investigation of anaphylaxis due to parenteral diet in an adult patient, in which polyethylene glycol (PEG) was the main suspected agent. Polyethylene glycols or macrogols comprise a family of hydrophilic polymers widely used in pharmaceutical, food, and cosmetic industry products. No study so far has examined the prevalence of PEG hypersensitivity, and its occurrence is likely to be underestimated. Suspected allergy to PEG should be considered in patients with immediate-type hypersensitivity reactions (HSRs) for PEG-containing products in which sensitization to active ingredients was excluded, patients with recurrent HSRs to unrelated medications and products, and patients with HSRs to certain brands or doses of the same drug. Immediate-type HSRs to PEGylated drugs are well established, but PEG-specific IgE has not yet been identified. This report shows that products normally considered to be innocuous should not be above suspicion during allergy investigation.

Assuntos

RESUMO

OBJECTIVE: To assess the risk factors, incidence and severity of adverse drug reactions in in-patients. METHODS: This prospective study evaluated 472 patients treated at a teaching hospital in Brazil between 2010 and 2013 by five medical specialties: Internal Medicine, General Surgery, Geriatrics, Neurology, and Clinical Immunology and Allergy. The following variables were assessed: patient age, gender, comorbidities, family history of hypersensitivity, personal and family history of atopy, number of prescribed drugs before and during hospitalization, hospital diagnoses, days of hospitalization. The patients were visited every other day, and medical records were reviewed by the investigators to detect adverse drug reactions. RESULTS: There were a total of 94 adverse drug reactions in 75 patients. Most reactions were predictable and of moderate severity. The incidence of adverse drug reactions was 16.2%, and the incidence varied, according to the medical specialty; it was higher in Internal Medicine (30%). Antibiotics were the most commonly involved medication. Chronic renal failure, longer hospital stay, greater number of diagnoses and greater number of medications upon admission were risk factors. For each medication introduced during hospitalization, there was a 10% increase in the rate of adverse drug reaction. In the present study, the probability of observing an adverse drug reaction was 1 in 104 patients per day. CONCLUSIONS: Adverse drug reactions are frequent and potentially serious and should be better monitored in patients with chronic renal failure or prolonged hospitalization and especially in those on 'polypharmacy' regimens. The rational use of medications plays an important role in preventing adverse drug reactions.

Assuntos

RESUMO

BACKGROUND: Skin prick test is the most widely used test for the diagnosis of IgE-mediated conditions. Commercial extracts are used for its performance, but in the case of fruits and vegetables it is preferable using fresh food. Although both tests possess a good safety profile, hypersensitivity reactions have been recorded. CLINICAL CASE: Forty-seven-year old woman with a history of persistent allergic rhinitis, sensitized to the pollen of grasses, olive and salsola; she was referred to an allergology department due to anaphylaxis triggered by the consumption of avocado, cantaloupe, carrots and watermelon. Minutes after skin prick test with standardized extract and skin prick with fresh foods, she developed dyspnea, pruritus, erythema, dizziness and sibilance; she was administered 0.5 mg of intramuscular adrenalin and 4 salbutamol inhalations and placed in the Trendelemburg position. Dyspnea persisted, and vital signs monitoring showed heart and respiratory rates increase and, hence, salbutamol was applied again, together with 2 L/min of oxygen delivered by nasal cannula, intravenous fluids and 100 mg intravenous hydrocortisone; improvement was observed at 40 minutes. The patient was hospitalized for 48 hours. CONCLUSIONS: Although skin tests are safe, the risk of hypersensitivity and anaphylactic reactions should not be ruled out, especially in susceptible patients.

Antecedentes: La prueba por punción epidérmica es la principal prueba para el diagnóstico de enfermedades mediadas por IgE. Para su realización se utilizan extractos comerciales; en el caso de frutas y verduras es mejor emplear alimentos frescos. Si bien ambas modalidades poseen un buen perfil de seguridad, se han registrado reacciones de hipersensibilidad. Caso clínico: Mujer de 47 años de edad con antecedentes de rinitis alérgica persistente, sensibilizada a polen de gramíneas, olivo y salsola; fue remitida a un servicio de alergología por anafilaxia desencadenada por el consumo de aguacate, melón, zanahoria y sandía. Minutos después de la punción cutánea con extracto estandarizado y punción cutánea con alimentos frescos, desarrolló disnea, prurito, eritema, mareo y sibilancias. Se le administraron 0.5 mg de adrenalina intramuscular y 4 inhalaciones de salbutamol; también fue colocada en posición de Trendelemburg. La disnea persistió y el monitoreo de los signos vitales mostró incremento de las frecuencias cardiaca y respiratoria, por lo que se aplicó nuevamente salbutamol, 2 L/min de oxígeno por cánula nasal, líquidos endovenosos y 100 mg de hidrocortisona intravenosa; a los 40 minutos se observó mejoría. La paciente fue hospitalizada durante 48 horas. Conclusiones: Aunque las pruebas cutáneas son seguras, no debe excluirse el riesgo de reacciones de hipersensibilidad y anafilaxia, especialmente en pacientes susceptibles.

Assuntos

RESUMO

Abstract Coccidioidomycosis is caused by Coccidioides immitis and Coccidioides posadasii fungi, which are endemic in certain locations in the American continent. They produce an asymptomatic infection in the majority of the exposed population, and in a lower proportion, a self-limited influenza-like illness, pneumonia or dissemination. Skin compromise could be secondary to the infection by the fungus or by a hypersensitivity reaction to the pulmonary infection. Primary skin compromise produces a chancriform, self-limited lesion, and the dissemination to the skin commonly produces nodules and abscesses, with a tendency to form fistulas. The most common hypersensitivity reaction is erythema nodosum, which is considered a marker of good prognosis. Treatment depends on the localization of the infection, the presence of dissemination, and the clinical conditions of the patient.

Resumen La coccidioidomicosis es causada por los hongos Coccidioides immitis y Coccidioides posadasii, los cuales son endémicos en determinadas localizaciones del continente americano. Producen infección asintomática en la mayoría de expuestos y en menor proporción cuadros gripales autolimitados, neumonía o diseminación. El compromiso en piel puede ser secundario a la infección por el hongo o por una reacción de hipersensibilidad a la infección pulmonar. El compromiso primario en piel produce una lesión chancreiforme, autolimitada y la diseminación a piel produce comúnmente nódulos y abscesos, con tendencia a la fistulización. La reacción de hipersensibilidad más común es el eritema nodoso, considerándose un marcador de buen pronóstico. El tratamiento depende de la localización de la infección, la presencia de diseminación y las condiciones clínicas del paciente.

RESUMO

Biological agents are used in the treatment of neoplastic, autoimmune, and inflammatory diseases and their clinical applications are becoming broader. Following their increased utilization, hypersensitivity reactions linked to these drugs have become more frequent, sometimes preventing the use of first-line therapies. The clinical presentation of hypersensitivity reactions to biological agents ranges from mild cutaneous manifestations to life-threatening reactions. In this scenario, rapid desensitization is a groundbreaking procedure that enables selected patients to receive the full treatment dose in a safe way, in spite of their immediate hypersensitivity reaction to the drug, and protects them against anaphylaxis. The aim of this review is to update and discuss some of the main biological agents used in clinical practice (rituximab, trastuzumab, cetuximab, ofatumumab, tocilizumab, brentuximab, omalizumab, and tumor necrosis factor alpha inhibitor agents) and their associated hypersensitivity reactions, including clinical presentations, diagnosis, and treatment in the acute setting. In addition, novel management options with rapid desensitization are presented.

Assuntos

RESUMO

El enalapril es un medicamento muy utilizado por su efectividad para el tratamiento de la hipertensión arterial; sin embargo, en algunos casos genera como efecto adverso reacciones liquenoides. El cuadro clínico de esta alteración es variado, manifiesta lesiones similares al liquen plano en piel y/o en mucosa bucal, resultado de una reacción de hipersensibilidad de un organismo susceptible a este medicamento. Presentamos el caso de un paciente femenino de 49 años de edad, quien refiere sangrado gingival espontáneo y al cepillado dental, dolor y ardor con alimentos ácidos, calientes y picantes desde hace tres años, multitratada con antibióticos y antimicóticos sin mejorar la sintomatología. Se diagnostica interdisciplinariamente por el Servicio de Periodoncia, Patología Bucal y Dermatología. El tratamiento bucal consistió en la enseñanza de una correcta higiene bucal junto con terapia corticoidea tópica y cambio del medicamento que provocó las lesiones.

Enalapril is a drug widely used due to its effectiveness in the treatment of blood hypertension cases, nevertheless, it occasionally generates lichenoid reactions as negative effect. The clinical picture of this alteration can be varied, in the skin and/or oral mucosae, it can induce lesions similar to those of lichen planus. These lesions could be the result of hypersensitivity reactions of a body which is susceptible to this drug. The present article documents the case of a 49 year old female patient, who sought consultation due to spontaneous gingival bleeding, bleeding caused by dental brushing, pain, and burning sensation with acid, hot or spicy foods. The condition had been present for the last three years. The patient had been repeatedly treated with antibiotics and antifungal drugs; nevertheless, these treatments proved to be unsuccessful. Oral Pathology, Dermatology and Periodontics Departments emitted a multi-disciplinary diagnosis. Oral treatment consisted of teaching appropriate oral hygiene techniques along with topical corticoid therapy, and substitution of the drug which induced the lesions.

RESUMO

WHAT IS KNOWN AND OBJECTIVE: Use of cisplatin can induce type I hypersensitivity reactions that may also be linked to the quality of the drug utilized. We observed cases of hypersensitivity that appeared to be associated with the brand of cisplatin used. The aim of this study was to compare two different brands of cisplatin in relation to type I hypersensitivity reactions. METHODS: Brand A was used in a tertiary care teaching hospital until 2012, and use of brand B started from January 2013, when the first hypersensitivity cases were observed. Patients were categorized based on symptom. Cisplatin of both brands was analysed by high-performance liquid chromatography (HPLC) and high-resolution electrospray ionization mass spectrometry (ESI-(+)-MS) and characterized according to US Pharmacopeia. RESULTS AND DISCUSSION: There were no cases of hypersensitivity associated with the use of cisplatin brand A, whereas four of 127 outpatients that used cisplatin brand B were affected. The two brands were in accordance with the US Pharmacopeia parameters, and there was no significant difference in the total platinum levels between the two brands when analysed by HPLC. However, high-resolution ESI-(+)-MS analyses show that brand B contains approximately 2.7 times more hydrolysed cisplatin than brand A. WHAT IS NEW AND CONCLUSION: The increase in the hydrolysed form of cisplatin found in brand B may be the cause of the hypersensitivity reaction observed in a subset of patients. We present the first study of the quality of drugs by high-resolution ESI-(+)-MS. Drug regulatory agencies and manufacturers should consider including measurement of hydrolysed cisplatin as a quality criterion for cisplatin formulations.

Assuntos

RESUMO

The increasing use of nanotechnologies in advanced therapies has allowed the observation of specific adverse reactions related to nanostructures. The toxicity of a novel liposome formulation of meglumine antimoniate in dogs with visceral leishmaniasis after single dose has been investigated. Groups of 12 animals received by the intravenous route a single dose of liposomal meglumine antimoniate (group I [GI], 6.5 mg Sb/kg), empty liposomes (GII) or isotonic saline (GIII). Evaluation of hematological and biochemical parameters showed no significant changes 4 days after administration. No undesired effects were registered in the GIII. However, adverse reactions were observed in 67.7% of dogs from both groups that received liposomal formulations. The side effects began moments after bolus administration and disappeared during the first 15 minutes after treatment. Prostation, sialorrhea and defecation were the most frequent clinical signs, registered in 33.3% and 41.6 % of animals from the groups GI and GII, respectively. Tachypnea, mydriasis, miosis, vomiting and cyanosis were also registered in both groups. The adverse reactions observed in this study were attributed to the activation of the complement system by lipid vesicles in a phenomenon known as Complement Activation-Related Pseudoallergy (CARPA). The influence of the physical-chemical characteristics of liposomal formulation in the triggering of CARPA is discussed.

O crescente uso das nanotecnologias nas terapias avançadas tem permitido a observação de reações adversas específicas relacionadas às nanoestruturas. A toxicidade de uma nova formulação lipossomal de antimoniato de meglumina após dose única foi avaliada em cães com leishmaniose visceral. Grupos de 12 animais receberam por via intravenosa uma dose única de antimoniato de meglumina lipossomal (grupo I [GI], 6,5 mg Sb/kg), lipossomas vazios (GII) ou solução salina isotônica (GIII). A avaliação de parâmetros hematológicos e bioquímicos não revelou alterações significativas quatro dias após a administração. Nenhum efeito indesejável foi registrado no GIII. No entanto, reações adversas foram observadas em 67,7% dos cães de ambos os grupos que receberam formulações lipossomais. Os efeitos colaterais iniciaram momentos após a administração em "bolus" e desapareceram no decurso dos primeiros 15 minutos após o tratamento. Prostração, sialorréia e defecação foram os sinais clínicos mais frequentes, registrados em 33,3% e 41,6% dos animais dos grupos GI e GII, respectivamente. Taquipnéia, midríase, miose, vômitos e cianose também foram registrados em ambos os grupos. As reações adversas observadas neste trabalho foram atribuídas à ativação do sistema complemento pelas vesículas lipídicas em fenômeno conhecido como Pseudoalergia Relacionada à Ativação do Complemento (PARAC). A influência das características físico-químicas da formulação lipossomal no desencadeamento de PARAC é abordada.

Assuntos

RESUMO

The increasing use of nanotechnologies in advanced therapies has allowed the observation of specific adverse reactions related to nanostructures. The toxicity of a novel liposome formulation of meglumine antimoniate in dogs with visceral leishmaniasis after single dose has been investigated. Groups of 12 animals received by the intravenous route a single dose of liposomal meglumine antimoniate (group I [GI], 6.5 mg Sb/kg), empty liposomes (GII) or isotonic saline (GIII). Evaluation of hematological and biochemical parameters showed no significant changes 4 days after administration. No undesired effects were registered in the GIII. However, adverse reactions were observed in 67.7% of dogs from both groups that received liposomal formulations. The side effects began moments after bolus administration and disappeared during the first 15 minutes after treatment. Prostation, sialorrhea and defecation were the most frequent clinical signs, registered in 33.3% and 41.6 % of animals from the groups GI and GII, respectively. Tachypnea, mydriasis, miosis, vomiting and cyanosis were also registered in both groups. The adverse reactions observed in this study were attributed to the activation of the complement system by lipid vesicles in a phenomenon known as Complement Activation-Related Pseudoallergy (CARPA). The influence of the physical-chemical characteristics of liposomal formulation in the triggering of CARPA is discussed.(AU)

O crescente uso das nanotecnologias nas terapias avançadas tem permitido a observação de reações adversas específicas relacionadas às nanoestruturas. A toxicidade de uma nova formulação lipossomal de antimoniato de meglumina após dose única foi avaliada em cães com leishmaniose visceral. Grupos de 12 animais receberam por via intravenosa uma dose única de antimoniato de meglumina lipossomal (grupo I [GI], 6,5 mg Sb/kg), lipossomas vazios (GII) ou solução salina isotônica (GIII). A avaliação de parâmetros hematológicos e bioquímicos não revelou alterações significativas quatro dias após a administração. Nenhum efeito indesejável foi registrado no GIII. No entanto, reações adversas foram observadas em 67,7% dos cães de ambos os grupos que receberam formulações lipossomais. Os efeitos colaterais iniciaram momentos após a administração em "bolus" e desapareceram no decurso dos primeiros 15 minutos após o tratamento. Prostração, sialorréia e defecação foram os sinais clínicos mais frequentes, registrados em 33,3% e 41,6% dos animais dos grupos GI e GII, respectivamente. Taquipnéia, midríase, miose, vômitos e cianose também foram registrados em ambos os grupos. As reações adversas observadas neste trabalho foram atribuídas à ativação do sistema complemento pelas vesículas lipídicas em fenômeno conhecido como Pseudoalergia Relacionada à Ativação do Complemento (PARAC). A influência das características físico-químicas da formulação lipossomal no desencadeamento de PARAC é abordada.(AU)

Assuntos

RESUMO

Introdução: O saco endolinfático tem sido apontado como o alvo das reações imuno-alérgicas da orelha interna. A prevalência de alergia em pacientes com Doença de Ménière foi estabelecida em torno de 41,6% para inalantes e 26,6% para alimentos, por Derebery em 2000, dados aumentados em relação à prevalência de alergia na população em geral, que, no Brasil, varia de 9% a 30% para inalantes e de 1% a 3% para alimentos. Objetivos: Avaliar a prevalência de reações de hipersensibilidade tipo I a inalantes e alimentos na população do setor de Otoneurologia do Hospital das Clínicas da Faculdade de Medicina de São Paulo e descrever os sintomas vestibulares dos pacientes. Casuística e método: Setenta e cinco pacientes com distúrbios do equilíbrio de origem periférica foram submetidos a questionário de caracterização clínica de sintomas cócleo-vestibulares e teste cutâneo (prick test) para 13 inalantes e 5 alimentos. Resultados: Vinte e cinco (33,3%) pacientes apresentaram prick test positivo a pelo menos um alérgeno inalante e 6 (8%) a pelo menos um alérgeno alimentar. Quatro pacientes apresentaram prick test positivo na ausência de sintomas alérgicos. Prevaleceu a queixa de tontura de caráter rotatório em proporções semelhantes entre os pacientes com prick test positivo e negativo. Conclusão: A prevalência de reações de hipersensibilidade tipo I a inalantes e a alimentos na população avaliada foi maior do que na população em geral. Os sintomas vestibulares não diferiram entre os pacientes da amostra, com prick test positivo ou negativo. No entanto, deve-se obter maior número de amostra para que os dados sejam confiáveis.

Introduction: The endolymphatic sac has been pointed out as the target of immuno-allergic reactions in the inner ear. The prevalence of allergy in patients with Ménières disease was established as approximately 41,6% for inhalants and 26,6% for food by Derebery in 2000, an increase in the data in relation to that of the prevalence of allergy in the general population, which in Brazil varies from 9% to 30% for inhalants and from 1% to 3% for food. Objectives: To evaluate the prevalence of reactions to type I hypersensitivity to inhalants and food in the population of the Otoneurological Section of the Clinics Hospital of the University of São Paulo Medicine School and to describe the vestibular symptoms of the patients. Method: Seventy-five patients with peripheral equilibrium disturbances who had answered a questionnaire of clinical characterization regarding cochlear-vestibular symptoms and undergone prick test for 13 inhalants and 5 types of food. Results: Twenty-five (33,3%) of the patients were positive for the prick test and for at least one allergen inhalant and 6 (8%) for at least one food allergen. Four patients were positive for the prick test in the absence of allergy symptoms. There was a prevalence of the complaint of rotatory dizziness in similar proportions among the patients with positive and negative prick test. Conclusion: The presence of type I hypersensitivity reactions to inhalants and food in the population evaluated was greater than in the general population. The vestibular symptoms did not differ among the patients in the sample, neither with positive or negative prick test results. However, a sample of greater number should be obtained for a higher confidence level of data results.

Assuntos